UNMET NEEDS AND BIOLOGIC USE AMONG PATIENTS WITH RHEUMATOID ARTHRITIS IN BRAZIL

Author(s)

de Renteria J*1;DiBonaventura M2;Suponcic S2, Pomerantz D2 1Kantar Health, Munich, Germany, 2Kantar Health, New York, NY, USA

OBJECTIVES: Despite their availability, it is unclear the extent to which biologic treatments are being used in Brazil. The current study assessed the unmet needs of patients with rheumatoid arthritis (RA) in Brazil and the degree to which biologic treatments are currently used.  METHODS: Data were obtained from the Brazil 2011 and 2012 National Health and Wellness Surveys (NHWS; N=24,000).  The Brazil NHWS is a self-reported nationally representative patient survey of the adult population (aged 18+), weighted to correct for any socioeconomic sampling bias.  Respondents in NHWS who reported a diagnosis of RA (n=137) were examined with respect to their sociodemographics, current treatments, health outcomes (e.g., Short Form 12v2), and biologic-related attitudes. Differences in health outcomes as a function of severity were examined using general linear models. RESULTS: Patients with RA were mostly female (59.12%) and had a mean age of (43.76 years). 36.50%, 43.07%, and 20.44% of patients were mild, moderate, and severe, respectively. Mean levels of physical health status decreased as severity increased (Mild=45.12; Moderate=41.50; Severe=38.49, p<.05). All severity levels were significantly lower than the population norm of 50 (ps<.05). Similar effects were observed for other health outcomes. Despite these unmet needs, only 60.92% of moderate-to-severe patients were currently being treated with a prescription medication and only 6.90% were using biologic therapy. Post-hoc analyses examined potential reasons for low biologic uptake among moderate-to-severe patients including significantly poorer access (20.27% of RA patients vs. 27.74% of non-RA patients had monthly household incomes above R$10,000) and attitudinal factors (29.33% reported a fear/strong fear of needles). CONCLUSIONS: Our analyses suggest significant decrements in health outcomes among patients with RA in Brazil and poor uptake in biologic therapies.  Although future research would need to more directly test our hypotheses, preliminary analyses suggest that poor access and attitudinal factors may play a role.

Conference/Value in Health Info

2013-09, ISPOR Latin America 2013, Buenos Aires, Argentina

Value in Health, Vol. 16, No. 7 (November 2013)

Code

PMS25

Topic

Epidemiology & Public Health

Topic Subcategory

Public Health

Disease

Musculoskeletal Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×